BREAST CANCER PANEL 3

  • Test Usage:
    ER & PR receptor assays are routinely performed on Breast carcinomas to assess responsiveness to endocrine therapy and prognosis. Her-2/neu expression shows responsiveness to Herceptin therapy.
  • Report Availability:
    Sample Daily by 6 pm Report 5 days: Blocks / Sections / Smears 7 days: Tissue
  • Sample Report:
45 Diagnostic Centers found for BREAST CANCER PANEL 3 in Lucknow